Patient-reported outcomes in adults with moderate to severe asthma after use of budesonide and formoterol administered via 1 pressurized metered-dose inhaler

Annals of Allergy, Asthma and Immunology

Volumn 101, Issue 5, 2008, Pages 463-473

  Chervinsky, Paul ^a,f   Baker, James ^b   Bensch, George ^c   Parasuraman, Bhash ^d   Boggs, Robert ^d,e   Martin, Paula ^d   O'Dowd, Liza ^d  

^a Northeast Medical Research Associates   (United States)

^b Baker Allergy   (United States)

^c Allergy Immunology and Asthma Medical Group Inc   (United States)

^d ASTRAZENECA   (United Kingdom)

^e PFIZER INC   (United States)

^f Northeast Medical Research Associates Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; FORMOTEROL; PLACEBO; SALBUTAMOL;

ADULT; AGED; ARTICLE; ASTHMA; ASTHMA QUALITY OF LIFE QUESTIONNAIRE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL OUTCOMES SURVEY SLEEP SCALE; METERED DOSE INHALER; MULTICENTER STUDY; OUTCOME ASSESSMENT; PATIENT SATISFACTION; PATIENT SATISFACTION WITH ASTHMA MEDICATION QUESTIONNAIRE; POWDER INHALER; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SELF REPORT; TREATMENT DURATION;

EID: 55849088317     PISSN: 10811206     EISSN: 15344436     Source Type: Journal    
DOI: 10.1016/S1081-1206(10)60284-0     Document Type: Article

References (23)

1. National Heart, Lung, and Blood Institute. National Asthma Education and Prevention Program Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. Bethesda, MD: National Heart, Lung, and Blood Institute; 2007.
2. Global Initiative for Asthma. Global strategy for asthma management and prevention - updated 2006. http://www.ginasthma.org. Accessed February 2008.
3. Juniper EF, Price DB, Stampone PA, Creemers JP, Mol SJ, Fireman P. Clinically important improvements in asthma-specific quality of life, but no difference in conventional clinical indexes in patients changed from conventional beclomethasone dipropionate to approximately half the dose of extrafine beclomethasone dipropionate. Chest. 2002;121:1824-1832.
4. Juniper EF, Svensson K, O'Byrne PM, et al. Asthma quality of life during 1 year of treatment with budesonide with or without formoterol. Eur Respir J. 1999;14:1038 -1043.
5. Juniper EF, Johnston PR, Borkhoff CM, Guyatt GH, Boulet LP, Haukioja A. Quality of life in asthma clinical trials: comparison of salmeterol and salbutamol. Am J Respir Crit Care Med. 1995;151:66-70.
6. US Department of Health and Human Services, Food and Drug Administration. Guidance for Industry: Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims: Draft Guidance. Washington, DC: US Department of Health and Human Services; February 2006.
7. Marquis P, Trudeau E. Quality of life and patient satisfaction: two important aspects in asthma therapy. Curr Opin Pulm Med. 2001;7(suppl 1):S18 -S20.
8. Jenkins CR, Thien FCK, Wheatley JR, Reddel HK. Traditional and patient-centered outcomes with three classes of asthma medication. Eur Respir J. 2005;26:36-44.
9. van Schayck CP, Dompeling E, Rutten MP, Folgering H, van den Boom G, van Weel C. The influence of an inhaled steroid on quality of life in patients with asthma or COPD. Chest. 1995;107:1199-1205.
10. Noonan M, Rosenwasser LJ, Martin P, O'Brien CD, O'Dowd L. Efficacy and safety of budesonide and formoterol in one pressurised metered-dose inhaler in adults and adolescents with moderate to severe asthma: a randomised clinical trial. Drugs. 2006;66:2235-2254.
11. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis. 1987;136:225-244.
12. Juniper EF, Guyatt GH, Epstein RS, Ferrie PJ, Jaeschke R, Hiller TK. Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials. Thorax. 1992;47:76-83.
13. Juniper EF, Guyatt GH, Willan A, Griffith LE. Determining a minimal important change in a disease-specific Quality of Life Questionnaire. J Clin Epidemiol. 1994;47:81-87.
14. Hays RD, Stewart AL. Sleep measures: definitions and issues. In: Stewart AL, Ware JE, eds. Measuring Functioning and Well-being: The Medical Outcomes Study Approach. Durham, NC: Duke University Press; 1992:235-259.
15. Mathias SD, Warren EH, Colwell HH, Sung JC. A new treatment satisfaction measure for asthmatics: a validation study. Qual Life Res. 2000;9:873-882.
16. Westfall PH, Ho SY, Prillaman BA. Properties of multiple intersection-union tests for multiple endpoints in combination therapy trials. J Biopharm Stat. 2001;11:125-138.
17. Frison L, Pocock SJ. Repeated measures in clinical trials: analysis using mean summary statistics and its implications for design. Stat Med. 1992;11:1685-1704.
18. Juniper EF, Jenkins C, Price MJ, James MH. Impact of inhaled salmeterol/fluticasone proprionate combination product versus budesonide on the health-related quality of life of patients with asthma. Am J Respir Crit Med. 2002;1:435-440.
19. Murphy K, Nelson H, Parasuraman B, Boggs R, Miller C, O'Dowd L. Budesonide and formoterol in one pressurized metered-dose inhaler improves patient-reported outcomes in adults with mild to moderate persistent asthma. Curr Med Res Opin. 2008;24:879-894.
20. Bergmann KC, Lindemann L, Braun R, Steinkamp G. Salmeterol/ fluticasone propionate (50/250 μg) combination is superior to double dose fluticasone (500 μg) for the treatment of symptomatic moderate asthma. Swiss Med Wkly. 2004;134:50-58.
21. Bateman ED, Boushey HA, Bousquet J, et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med. 2004;170:836-844.
22. O'Byrne PM, Barnes PJ, Rodriguez-Roisin R, et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med. 2001;164:1392-1397.
23. Center for Drug Evaluation and Research. ADVAIR DISKUS (Fluticasone Proprionate and Salmeterol Xinafoate) Inhalation Powder. Application number: 21-077. http://www.fda.gov/cder/foi/nda/2000/21077_AdvairDiskus.htm. Accessed March 2007.